© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Sizing Up European Biosimilar Competition
We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European markets they feel need the most work.
Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.
A market’s structure and incentives are critical in ensuring that companies that develop medications such as biosimilars have a competitive environment to thrive. Several countries in Europe implement tender systems, which are used to promote the lowest-cost biosimilar and may discourage competitors from contending after an unsuccessful bid. However, 2 officials of Medicines for Europe designed a scorecard of European markets to show which have robust competition and which do not.
We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European countries they feel need the most work.
To check out the scorecard, click here.
To learn more about Medicines for Europe, click here.
